CERS Cerus Corporation

4.48
+0.41  (+10%)
Previous Close 4.07
Open 4.41
Price To Book 10.42
Market Cap 636,557,958
Shares 142,088,830
Volume 2,305,311
Short Ratio
Av. Daily Volume 949,091
Stock charts supplied by TradingView

NewsSee all news

  1. French Hemovigilance Report Highlights Safety and Effectiveness of INTERCEPT Platelets During First Full Year of 100% Production and Routine Use

    Cerus Corporation (NASDAQ:CERS) is pleased to announce the recent publication of the 16th Annual Hemovigilance report by the French National Agency for Medicines and Health Products (ANSM) which oversees the safety of

  2. Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2019 Product Revenue

    Company provides 2020 product revenue guidance range of $89 million to $93 million representing growth of approximately 20% to 25% over preliminary 2019 full year results Cerus Corporation (NASDAQ:CERS) announced today

  3. Cerus Corporation to Present at the Stifel 2019 Healthcare Conference

    Cerus Corporation (NASDAQ:CERS) announced today that Kevin D. Green, Cerus' chief financial officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 2:25 p.m. ET in New York

  4. Cerus Corporation to Present at the Stephens Nashville Investment Conference

    Cerus Corporation (NASDAQ:CERS) announced today that Kevin D. Green, Cerus' chief financial officer, will present at the Stephens Nashville Investment Conference on Wednesday, November 13, 2019 at 10:30 a.m. CT. A

  5. Cerus Corporation Announces Third Quarter 2019 Results

    Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter ended September 30, 2019. Recent developments and highlights include: FDA issued its final guidance document on strategies to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met endpoints - January 23, 2018. CE mark submission due 2H 2018.
INTERCEPT
Chronic anemia in thalassemia patients
PMA approved Dec 18 2014
INTERCEPT
Platelets
PMA approved Dec 16 2014
INTERCEPT B123
Plasma
Phase 3 initiation announced December 19, 2018.
INTERCEPT (ReCePI)
Patients undergoing complex cardiac surgery procedures

Latest News

  1. French Hemovigilance Report Highlights Safety and Effectiveness of INTERCEPT Platelets During First Full Year of 100% Production and Routine Use

    Cerus Corporation (NASDAQ:CERS) is pleased to announce the recent publication of the 16th Annual Hemovigilance report by the French National Agency for Medicines and Health Products (ANSM) which oversees the safety of

  2. Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2019 Product Revenue

    Company provides 2020 product revenue guidance range of $89 million to $93 million representing growth of approximately 20% to 25% over preliminary 2019 full year results Cerus Corporation (NASDAQ:CERS) announced today

  3. Cerus Corporation to Present at the Stifel 2019 Healthcare Conference

    Cerus Corporation (NASDAQ:CERS) announced today that Kevin D. Green, Cerus' chief financial officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 2:25 p.m. ET in New York

  4. Cerus Corporation to Present at the Stephens Nashville Investment Conference

    Cerus Corporation (NASDAQ:CERS) announced today that Kevin D. Green, Cerus' chief financial officer, will present at the Stephens Nashville Investment Conference on Wednesday, November 13, 2019 at 10:30 a.m. CT. A

  5. Cerus Corporation Announces Third Quarter 2019 Results

    Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter ended September 30, 2019. Recent developments and highlights include: FDA issued its final guidance document on strategies to

  6. Cerus Corporation to Release Third Quarter 2019 Results and to Discuss Recent FDA Guidance for Bacterial Safety of Platelets on October 30, 2019

    Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2019 results will be released on Wednesday, October 30, 2019, after the close of the stock market. The Company will host a conference call and

  7. Cerus Corporation Announces Schedule of Presentations at the 2019 AABB Annual Meeting

    Cerus Corporation (NASDAQ:CERS) announced today its schedule of key events and presentations at the 2019 AABB Annual Meeting which is taking place in San Antonio, Texas on October 19th through October 22nd. The AABB

  8. Cerus Corporation Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection and Transfusion

    Cerus Corporation (NASDAQ:CERS) applauds the publication of the FDA final guidance document titled Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and

  9. Cerus Corporation to Present at the 2019 Cantor Global Healthcare Conference

    Cerus Corporation (NASDAQ:CERS) today announced that Kevin D. Green, Cerus' vice president, finance and chief financial officer will present and provide a corporate update at the 2019 Cantor Global Healthcare Conference

  10. Cerus Corporation to Participate in Upcoming Investor Conferences

    Cerus Corporation (NASDAQ:CERS) today announced that the Company will participate in two upcoming investor conferences. William ‘Obi' Greenman, Cerus' president and chief executive officer, is scheduled to present at